Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes

被引:47
作者
Chamaon, K
Kirches, E
Kanakis, D
Braeuninger, S
Dietzmann, K
Mawrin, C
机构
[1] Univ Magdeburg, Dept Neuropathol, D-39120 Magdeburg, Germany
[2] Helios Klinikum Berlin Buch, Dept Pathol, D-13125 Berlin, Germany
关键词
pituitary tumor transforming gene; Igf-I; insulin; astrocytoma;
D O I
10.1016/j.bbrc.2005.03.124
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The reasons for overexpression of the oncogene pituitary tumor transforming gene (PTTG) in tumors are still not fully understood. A possible influence of the insulin-like growth factor I (Igf-I) may be of interest, since enhanced Igf-I signalling was reported in various human tumors. We examined the influence of Igf-I and insulin on PTTG expression in human astrocytoma cells in comparison to proliferating non-neoplastic rat embryonal astrocytes. PTTG mRNA expression and protein levels were increased in malignant astrocytes treated with Igf-I or insulin, whereas in rat embryonic astrocytes PTTG expression and protein levels increased only when cells were exposed to Igf-I. Enhanced transcription did not occur after treatment with inhibitors of phosphoinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK). blocking the two basic signalling pathways of Igf-I and insulin. In addition to this transcriptional regulation, both kinases directly bind to PTTG. Suggesting U Second regulatory route by phosphorylation. However, the interaction of endogenous PTTG with MAPK and PI3K. as well its PTTG phosphorylation were independent from Igf-I or insulin. The latter results were also found in human testis. which contains high PTTG levels it,, well as in nonneoplastic astrocytes. This suggest, that PI3K and MAPK signalling is involved in PTTG regulation not only in malignant astrocytomas but also in non-tumorous cells. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:86 / 92
页数:7
相关论文
共 18 条
[1]   Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas [J].
Andrews, DW ;
Resnicoff, M ;
Flanders, AE ;
Kenyon, L ;
Curtis, M ;
Merli, G ;
Baserga, R ;
Iliakis, G ;
Aiken, RD .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2189-2200
[2]   INSULIN-LIKE GROWTH-FACTOR-I STIMULATES TYROSINE PHOSPHORYLATION OF ENDOGENOUS C-CRK [J].
BEITNERJOHNSON, D ;
LEROITH, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (10) :5187-5190
[3]  
Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9
[4]   A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product [J].
Chien, WW ;
Pei, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (25) :19422-19427
[5]   Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells [J].
Clem, AL ;
Hamid, T ;
Kakar, SS .
GENE, 2003, 322 :113-121
[6]   INSULIN AND INSULIN-LIKE GROWTH FACTOR-I IN BRAIN-TUMORS - BINDING AND INVITRO EFFECTS [J].
GLICK, RP ;
GETTLEMAN, R ;
PATEL, K ;
LAKSHMAN, R ;
TSIBRIS, JCM .
NEUROSURGERY, 1989, 24 (06) :791-797
[7]   Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis [J].
Heaney, AP ;
Horwitz, GA ;
Wang, ZY ;
Singson, R ;
Melmed, S .
NATURE MEDICINE, 1999, 5 (11) :1317-1321
[8]  
Hirano H, 1999, Neuro Oncol, V1, P109, DOI 10.1093/neuonc/1.2.109
[9]   ROLE OF INSULIN-LIKE GROWTH-FACTORS IN PERIPHERAL-NERVE REGENERATION [J].
ISHII, DN ;
GLAZNER, GW ;
PU, SF .
PHARMACOLOGY & THERAPEUTICS, 1994, 62 (1-2) :125-144
[10]   Signalling through IGF-I and insulin receptors: where is the specificity? [J].
Kim, JJ ;
Accili, D .
GROWTH HORMONE & IGF RESEARCH, 2002, 12 (02) :84-90